# Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC

> **NCT05831969** · PHASE2 · UNKNOWN · sponsor: **Shenyang Tenth People's Hospital** · enrollment: 23 (estimated)

## Conditions studied

- Advanced HCC

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT05831969
- **Lead sponsor:** Shenyang Tenth People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-05
- **Primary completion:** 2025-06-05
- **Final completion:** 2025-10-05
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2023-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05831969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05831969, "Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05831969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*